| Literature DB >> 30405108 |
Hana Kahleova1, Rebecca Fleeman2, Adela Hlozkova2, Richard Holubkov3, Neal D Barnard2,4.
Abstract
BACKGROUND AND OBJECTIVES: A plant-based diet is an effective strategy in the treatment of obesity. In this 16-week randomized clinical trial, we tested the effect of a plant-based diet on body composition and insulin resistance. As a part of this trial, we investigated the role of plant protein on these outcomes. SUBJECTS AND METHODS: Overweight participants (n = 75) were randomized to follow a plant-based (n = 38) or a control diet (n = 37). Dual X-ray Absorptiometry assessed body composition, Homeostasis Model Assessment (HOMA-IR) assessed insulin resistance, and a linear regression model was used to test the relationship between protein intake, body composition, and insulin resistance.Entities:
Mesh:
Year: 2018 PMID: 30405108 PMCID: PMC6221888 DOI: 10.1038/s41387-018-0067-4
Source DB: PubMed Journal: Nutr Diabetes ISSN: 2044-4052 Impact factor: 5.097
Baseline characteristics of study population
| Characteristic | |
|---|---|
| Age (years) | 53.2 ± 12.6 |
| Sex (number, %) | |
| Male | 8 (11%) |
| Female | 67 (89%) |
| Race, (number, %) | |
| White | 34 (45%) |
| Black | 34 (45%) |
| Asian, Pacific Islander | 4 (5%) |
| American Indian, Eskimo, Aleut | 2 (3%) |
| N/A—did not disclose | 1 (1%) |
| Ethnicity, (number, %) | |
| Non-hispanic | 64 (85%) |
| Hispanic | 6 (8%) |
| N/A—did not disclose | 5 (7%) |
| Education | |
| College | 37 (49%) |
| Graduate degree | 37 (49%) |
| NA | 1 (1%) |
| Medications | |
| Lipid-lowering therapy (%) | 9 (12%) |
| Antihypertensive therapy (%) | 18 (24%) |
| Thyroid medications (%) | 9 (12%) |
Changes in dietary intake of amino acids (g) during the study.
| Control group | Vegan group | Treatment effect | ||||
|---|---|---|---|---|---|---|
| Activity and diet | Baseline | Week 16 | Baseline | Week 16 | ||
| Physical activity (METs) | 2642 (1476–3809) | 2575 (1169–3980) | 2207 (1444–2969) | 2490 (1586–3395) | +351 (−1143 to +1846) | 0.46 |
| Caloric intake (kcal.day−1) | 1923 (1627–2219) | 1582 (1368–1795)** | 1851 (1695–2007) | 1450 (1249–1652)*** | −60 (−352 to+233) | 0.69 |
| Carbs (% of daily energy) | 45.5 (42.6–48.4) | 46.6 (42.9–50.4) | 46.1 (43.5–48.8) | 69.6 (67.3–71.8)*** | +22.3 (+17.7 to +26.9) | <0.001 |
| Fats (% of daily energy) | 35.6 (32.3–38.9) | 35.0 (31.5–38.4) | 36.1 (34.0–38.1) | 17.5 (15.5–19.4)*** | −17.9 (−22.3 to −13.6) | <0.001 |
| Proteins (% of daily energy) | 16.00 (14.94–17.07) | 16.99 (15.45–18.52) | 16.77 (15.36–18.19) | 12.26 (11.26–13.25)*** | −5.50 (−7.90 to −3.11) | <0.001 |
| Total protein (g/day) | 75.4 (65.4–85.4) | 66.8 (57.3–76.2) | 76.5 (68.8–84.2) | 50.8 (42.4–59.3)*** | −17.0 (−30.5 to −3.4) | 0.01 |
| Animal protein (g) | 45.16 (37.2–53.1) | 39.68 (30.5–48.9) | 45.01 (38.4–51.7) | 3.34 (0.66–6.02)*** | −36.2 (−48.4 to −24.0) | <0.001 |
| Plant protein (g) | 30.3 (25.8–34.7) | 27.1 (22.8–31.4) | 31.5 (26.7–36.2) | 47.5 (39.7–55.3)*** | +19.2 (+10.5 to +28.0) | <0.001 |
| Cholesterol intake (mg.day−1) | 290 (220–360) | 212 (149–275) | 264 (213–315) | 6.5 (2.5-10.5)*** | −180 (−278 to −82) | <0.001 |
| Tryptophan (g) | 0.92 (0.78–1.06) | 0.80 (0.67–0.92) | 0.93 (0.83–1.02) | 0.61 (0.50–0.72)*** | −0.19 (−0.38 to −0.01) | 0.04 |
| Threonine (g) | 2.92 (2.51–3.33) | 2.58 (2.19–2.97) | 2.93 (2.62–3.25) | 1.78 (1.47–2.09)*** | −0.81 (−1.36 to −0.27) | 0.004 |
| Isoleucine (g) | 3.32 (2.85–3.79) | 2.94 (2.50–3.37) | 3.41 (3.04–3.77) | 2.03 (1.67–2.40)*** | −0.99 (−1.62 to −0.35) | 0.003 |
| Leucine (g) | 5.80 (5.01–6.59) | 5.07 (4.29–5.85) | 5.83 (5.23–6.43) | 3.68 (3.00–4.36)*** | −1.41 (−2.49 to −0.34) | 0.01 |
| Lysine (g) | 4.83 (4.13–5.53) | 4.33 (3.61–5.05) | 4.90 (4.33–5.46) | 2.50 (2.00–3.01)*** | −1.90 (−2.89 to −0.91) | <0.001 |
| Methionine (g) | 1.62 (1.39–1.86) | 1.44 (1.20–1.67) | 1.66 (1.47–1.85) | 0.75 (0.62–0.88)*** | −0.72 (−1.05 to −0.39) | <0.001 |
| Cysteine (g) | 1.03 (0.89–1.18) | 0.90 (0.76–1.03) | 1.04 (0.94–1.15) | 0.78 (0.65–0.91)*** | −0.13 (−0.31 to +0.06) | 0.19 |
| Phenylalanine (g) | 3.32 (2.89–3.75) | 2.91 (2.51–3.30) | 3.38 (3.03–3.72) | 2.38 (1.95-2.81)*** | −0.58 (−1.20 to +0.03) | 0.06 |
| Tyrosine (g) | 2.50 (2.16–2.84) | 2.20 (1.86–2.54) | 2.58 (2.31–2.86) | 1.42 (1.19–1.66)*** | −0.86 (−1.34 to −0.39) | <0.001 |
| Valine (g) | 3.77 (3.24–4.29) | 3.30 (2.83–3.78) | 3.84 (3.44–4.24) | 2.43 (2.00–2.86)*** | −0.95 (−1.65 to −0.24) | 0.009 |
| Arginine (g) | 4.37 (3.76–4.99) | 3.91 (3.40–4.43) | 4.30 (3.84–4.77) | 2.98 (2.51–3.45)*** | −0.87 (−1.64 to −0.09) | 0.03 |
| Histidine (g) | 1.98 (1.72–2.24) | 1.74 (1.48–2.00) | 2.02 (1.80–2.24) | 1.23 (1.01–1.44)*** | −0.55 (−0.93 to −0.17) | 0.005 |
| Alanine (g) | 3.56 (3.07–4.04) | 3.18 (2.72–3.64) | 3.60 (3.21–3.99) | 2.21 (1.84–2.58)*** | −1.01 (−1.67 to −0.35) | 0.003 |
| Aspartic acid (g) | 6.88 (5.94–7.82) | 6.21 (5.41–7.01) | 6.81 (6.14–7.49) | 4.91 (4.04–5.79)*** | −1.23 (−2.47 to +0.01) | 0.05 |
| Glutamic acid (g) | 14.22 (12.40–16.05) | 12.44 (10.74–14.15)* | 14.41 (12.95–15.88) | 10.73 (9.01–12.45)*** | −1.91 (−4.36 to +0.55) | 0.13 |
| Glycine (g) | 3.11 (2.69–3.53) | 2.80 (2.42–3.19) | 3.14 (2.81–3.47) | 1.98 (1.65–2.31)*** | −0.86 (−1.43 to −0.28) | 0.004 |
| Proline (g) | 4.57 (3.94–5.20) | 3.86 (3.23–4.49)* | 4.66 (4.19–5.13) | 3.15 (2.58–3.73)*** | −0.80 (−1.67 to +0.07) | 0.072 |
| Serine (g) | 3.41 (2.95–3.87) | 2.98 (2.56–3.40)* | 3.45 (3.10–3.79) | 2.44 (1.99–2.89)*** | −0.57 (−1.18 to +0.03) | 0.06 |
Data are means ± SD
Listed p-values are for interactions between group and time assessed by repeated measures ANOVA. *p < 0.05; **p < 0.01; ***p < 0.001 for within-group changes from baseline assessed by paired comparison t-tests
Fig. 1Changes in amino acid (AA) profiles between vegans and controls at baseline and 16 weeks. (A) Control Baseline, (B) Vegan Baseline (C) Control Final, (D) Vegan Final
Fig. 2Changes in body weight, fat mass, and insulin resistance in the vegan and control group at baseline and after 16 weeks. (A) Body Mass Index (BMI), Gxt p < 0.001; (B) Body Weight, Gxt p < 0.001; ; (C) Fat Mass, Gxt p < 0.001; (D) Visceral Fat Volume, Gxt p < 0.001; and (E) Homeostatic Model Assessment Insulin Resistance (HOMA-IR), Gxt p=0.004. Gxt is interaction between group and time from the ANOVA model. *** for p < 0.001. Data are given as means with 95% confidence intervals
Fig. 3Regression models for changes in (A) Animal protein and fat mass: r = +0.39; p = 0.001; (B) Vegetable protein and fat mass: r = -0.30; p = 0.011; (C) % Leucine intake and fat mass: r = +0.40; p < 0.001; and (D) % Histidine intake and HOMA-IR (Homeostasis Model Assessment) insulin resistance: r = +0.38; p = 0.003